Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years

Author： Kawai Masaaki   Malone Kathleen E.   Tang Mei-Tzu C.   Li Christopher I.  

Publisher： Blackwell Publishing

E-ISSN： 1097-0142|120|10|1548-1556

ISSN： 0008-543X

Source： Cancer, Vol.120, Iss.10, 2014-05, pp. : 1548-1556

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years

By Kawai Masaaki   Malone Kathleen E.   Tang Mei-Tzu C.   Li Christopher I.  

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 1026-1034

Blackwell Publishing

Access to resources Recommend Favorite

Lapatinib: In Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer

By Curran Monique P.  

Drugs, Vol. 70, Iss. 11, 2010-07 ,pp. : 1411-1422

Adis International

Access to resources Recommend Favorite

Treatment of Estrogen Receptor-Positive Breast Cancer

By  

Current Medicinal Chemistry, Vol. 20, Iss. 5, 2013-02 ,pp. : 596-604

Bentham Science Publishers

Access to resources Recommend Favorite

Body mass index (BMI) is not a predictor of increased hospital use among individuals aged 75 years

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 443, 2003-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Trastuzumab: In HER2 and Hormone Receptor Co-Positive Metastatic Breast Cancer

By Orman Jennifer S.   Perry Caroline M.  

Drugs, Vol. 67, Iss. 18, 2007-01 ,pp. : 2781-2789

Adis International

Access to resources Recommend Favorite